A population‐based study of chronic eosinophilic leukemia‐not otherwise specified in the United States-Reference-Cited by-同舟云学术

A population‐based study of chronic eosinophilic leukemia‐not otherwise specified in the United States

Published:2020-07-21 Issue:10 Volume:95 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Ruan Gordon J.¹^ORCID,Smith Caleb J.¹^ORCID,Day Courtney²,Harmsen William S.²,Zblewski Darci L.³,Alkhateeb Hassan³,Begna Kebede³^ORCID,Al‐Kali Aref³,Litzow Mark R.³^ORCID,Hogan William³,Gangat Naseema³,Patnaik Mrinal S.³^ORCID,Pardanani Animesh³,Tefferi Ayalew³^ORCID,Go Ronald S.³,Shah Mithun V.³^ORCID

Affiliation:

1. Department of Internal Medicine Mayo Clinic Rochester Minnesota USA

2. Division of Biomedical Statistics and Informatics Mayo Clinic Rochester Minnesota USA

3. Division of Hematology Mayo Clinic Rochester Minnesota USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25906

Reference6 articles.

1. World Health Organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management

2. Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation

3. WHO defined chronic eosinophilic leukemia, not otherwise specified ( CEL , NOS ): A contemporary series from the Mayo Clinic

4. Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence

5. Surveillance Epidemiology and End Results (SEER) Program 1975–2017 (SEER*Stat Database: SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisana Cases Nov 2018 Sub (2000–2016) Katrina/Rita Population Adjustment ‐ Linked To County Attributes ‐ Total U.S. 1969–2017 Counties National Cancer Institute DCCPS Surveillance Research Program Surveillance Systems Branch released in April 2018 based on the November 2017 submission).www.seer.cancer.gov. Accessed January 2020.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytogénétique Hématologique (GFCH);Current Research in Translational Medicine;2023-10

2. Eosinophilia: hypereosinophilic syndrome vs. eosinophilic granulomatosis with polyangiitis;Zeitschrift für Rheumatologie;2023-04-26

3. Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?;Blood Reviews;2023-03

4. World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management;American Journal of Hematology;2021-10-08

5. Diagnostik und Therapie von Eosinophilien;InFo Hämatologie + Onkologie;2021-02